LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

532

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2029

Study Completion Date

October 1, 2030

Conditions

Hypertrophic Cardiomyopathy (HCM)

Interventions

DRUG

Anticoagulant treatment Rivaroxaban

Anticoagulant treatment Rivaroxaban in addition to best medical therapy

OTHER

Best medical therapy

Best medical therapy alone

All Listed Sponsors

lead

Rennes University Hospital

OTHER